The nation of Zimbabwe has declined a substantial US health deal worth $367m (£272m) spanning five years due to Washington's request for confidential biological samples.
This move became public after a internal memorandum from December was leaked, revealing that President Emmerson Mnangagwa believed the agreement was "lopsided".
An official spokesman has since explained that the United States was demanding access to genetic material for research and commercial gain while was not willing to guarantee the benefits from future medical innovations.
"We will now turn to the challenging and unfortunate task of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated more than $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for further talks to secure a agreement agreeable to both sides so the nation's critical HIV programme can be sustained.
Broader Context
This development follows a similar situation in Kenya, where a high court suspended a related deal with the US following concerns were filed about the safety of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had managed assistance for the American government, but Trump argued its spending was "inefficient" and his administration was pursuing direct bilateral agreements to boost transparency and responsibility.
According to reports, 16 nations in Africa have so far signed these new health pacts, representing more than $18.3bn in new funding.
Specifics of the Rejected Deal
This assistance for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation might have yielded extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving HIV treatment via American-funded initiatives," Tremont said.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, with no corresponding promise of benefiting from any medical innovations – like new medicines or tests – that could result from that provided information," he stated.
"Put simply, our country would supply the basic resources for medical research with no assurance that the end products would be accessible to our people if a new pandemic emerge."
National Interest and Global Health
Mangwana further said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were undermining structures already set up through the global organization.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to deal with future global health emergencies.
"This mechanism is intended to ensure that when a country provides its samples, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the funds to develop them."
The government's concerns regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We welcome continued dialogue with our American counterparts on how future co-operation might be designed in a way that respects the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body expressed it acknowledged the government's concerns, but recommended that talks must proceed since much of the nation's HIV programmes relied on foreign aid.
"In cases where specific concerns exist, including those involving information security or implementation frameworks, these can often be addressed via detailed discussion and mutually agreed protections," the group added.
This impasse underscores the continuing challenges between accepting vital foreign assistance and protecting a country's data in an increasingly data-driven world.